Cargando…

Cellular Receptors of Amyloid β Oligomers (AβOs) in Alzheimer’s Disease

It is estimated that Alzheimer’s disease (AD) affects tens of millions of people, comprising not only suffering patients, but also their relatives and caregivers. AD is one of age-related neurodegenerative diseases (NDs) characterized by progressive synaptic damage and neuronal loss, which result in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mroczko, Barbara, Groblewska, Magdalena, Litman-Zawadzka, Ala, Kornhuber, Johannes, Lewczuk, Piotr
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6073792/ https://www.ncbi.nlm.nih.gov/pubmed/29954063 http://dx.doi.org/10.3390/ijms19071884

Ejemplares similares

The Role of Protein Misfolding and Tau Oligomers (TauOs) in Alzheimer’s Disease (AD)
por: Mroczko, Barbara, et al.
Publicado: (2019)

The Role of Selected Chemokines and Their Receptors in the Development of Gliomas
por: Groblewska, Magdalena, et al.
Publicado: (2020)

Clinical significance of fluid biomarkers in Alzheimer’s Disease
por: Lewczuk, Piotr, et al.
Publicado: (2020)

Biomarkers for the Diagnosis of Alzheimer’s Disease in Clinical Practice: The Role of CSF Biomarkers during the Evolution of Diagnostic Criteria
por: Dulewicz, Maciej, et al.
Publicado: (2022)

Alzheimer’s Disease—Biochemical and Psychological Background for Diagnosis and Treatment
por: Beata, Bocwinska-Kiluk, et al.
Publicado: (2023)

Amyloid β-protein oligomers and Alzheimer’s disease
por: Hayden, Eric Y, et al.
Publicado: (2013)

β-Amyloid oligomers in aging and Alzheimer’s disease
por: Zahs, Kathleen R., et al.
Publicado: (2013)

Cellular Prion Protein as a Receptor of Toxic Amyloid-β42 Oligomers Is Important for Alzheimer’s Disease
por: Zhang, Yuan, et al.
Publicado: (2019)

Cerebrospinal Fluid Aβ(42/40) Corresponds Better than Aβ(42) to Amyloid PET in Alzheimer’s Disease
por: Lewczuk, Piotr, et al.
Publicado: (2016)

Postsynaptic Receptors for Amyloid-β Oligomers as Mediators of Neuronal Damage in Alzheimer’s Disease
por: Dinamarca, Margarita C., et al.
Publicado: (2012)

Doxycycline for Alzheimer’s Disease: Fighting β-Amyloid Oligomers and Neuroinflammation
por: Balducci, Claudia, et al.
Publicado: (2019)

Mutations in the β-amyloid precursor protein in familial Alzheimer’s disease increase Aβ oligomer production in cellular models
por: Ohshima, Yoichi, et al.
Publicado: (2018)

The Toxicity of Amyloid β Oligomers
por: Zhao, Li Na, et al.
Publicado: (2012)

CSF amyloid-β-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia
por: Bibl, Mirko, et al.
Publicado: (2006)

Distributions of Aβ42 and Aβ42/40 in the Cerebrospinal Fluid in View of the Probability Theory
por: Lewczuk, Piotr, et al.
Publicado: (2021)

Amyloid-β oligomers set fire to inflammasomes and induce Alzheimer's pathology
por: Salminen, Antero, et al.
Publicado: (2008)

Breaking the Code of Amyloid-β Oligomers
por: Lesné, Sylvain E.
Publicado: (2013)

The Toxicity and Polymorphism of β-Amyloid Oligomers
por: Huang, Ya-ru, et al.
Publicado: (2020)

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
por: Hansson, Oskar, et al.
Publicado: (2019)

Specific Receptors for the Chemokines CXCR2 and CXCR4 in Pancreatic Cancer
por: Litman-Zawadzka, Ala, et al.
Publicado: (2020)

Pro- and Antiangiogenic Factors in Gliomas: Implications for Novel Therapeutic Possibilities
por: Groblewska, Magdalena, et al.
Publicado: (2021)

Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer’s disease
por: Baldeiras, Inês, et al.
Publicado: (2019)

Phagocytosis and LPS alter the maturation state of β-amyloid precursor protein and induce different Aβ peptide release signatures in human mononuclear phagocytes
por: Spitzer, Philipp, et al.
Publicado: (2010)

Combined Analysis of CSF Tau, Aβ42, Aβ1–42% and Aβ1–40(ox)% in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia
por: Bibl, Mirko, et al.
Publicado: (2010)

Cellular Prion Protein Mediates Impairment of Synaptic Plasticity by Amyloid-β Oligomers
por: Laurén, Juha, et al.
Publicado: (2009)

Evaluating Amyloid-β Oligomers in Cerebrospinal Fluid as a Biomarker for Alzheimer’s Disease
por: Hölttä, Mikko, et al.
Publicado: (2013)

Soluble amyloid-β oligomers as synaptotoxins leading to cognitive impairment in Alzheimer’s disease
por: Ferreira, Sergio T., et al.
Publicado: (2015)

Hyperactivity Induced by Soluble Amyloid-β Oligomers in the Early Stages of Alzheimer's Disease
por: Hector, Audrey, et al.
Publicado: (2021)

The biogenesis and biology of amyloid β oligomers in the brain
por: Ashe, Karen Hsiao
Publicado: (2020)

YKL-40 as a Potential Biomarker and a Possible Target in Therapeutic Strategies of Alzheimer’s Disease
por: Muszyński, Paweł, et al.
Publicado: (2017)

A Luminex Assay Detects Amyloid β Oligomers in Alzheimer’s Disease Cerebrospinal Fluid
por: Herskovits, Adrianna Z., et al.
Publicado: (2013)

Amyloid-β oligomers unveil a novel primate model of sporadic Alzheimer's disease
por: Jebelli, Joseph D., et al.
Publicado: (2015)

Stabilization of a Membrane-Associated Amyloid-β Oligomer for Its Validation in Alzheimer's Disease
por: Serra-Batiste, Montserrat, et al.
Publicado: (2018)

Target engagement in an alzheimer trial: Crenezumab lowers amyloid β oligomers in cerebrospinal fluid
por: Yang, Ting, et al.
Publicado: (2019)

The Therapeutic and Diagnostic Potential of Amyloid β Oligomers Selective Antibodies to Treat Alzheimer’s Disease
por: Viola, Kirsten L., et al.
Publicado: (2022)

ACU193: An Immunotherapeutic Poised to Test the Amyloid β Oligomer Hypothesis of Alzheimer’s Disease
por: Krafft, Grant A., et al.
Publicado: (2022)

Oligomer Formation by Amyloid-β42 in a Membrane-Mimicking Environment in Alzheimer’s Disease
por: Rosenberry, Terrone L., et al.
Publicado: (2022)

Characterization of a Novel Mouse Model of Alzheimer’s Disease—Amyloid Pathology and Unique β-Amyloid Oligomer Profile
por: Liu, Peng, et al.
Publicado: (2015)

The Role of Gut Microbiota and Gut–Brain Interplay in Selected Diseases of the Central Nervous System
por: Doroszkiewicz, Julia, et al.
Publicado: (2021)

Molecular Biomarkers and Their Implications for the Early Diagnosis of Selected Neurodegenerative Diseases
por: Doroszkiewicz, Julia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bio8j9m5gpi7e42pj12iitr7ae